Currently, animal-borne viral diseases seriously threaten the development of the world's breeding industry, especially in economically underdeveloped regions. The diseases cause tens of billions of dollars in economic losses every year. The pathogen comprised avian diseases, swine diseases, cattle diseases, sheep and goat diseases, etc. Research from revealing the mechanisms of pathogenic infection to vaccine prevention of diseases can provide beneficial effects on the control of animal-borne infectious diseases. In this Research Topic, we will conduct a comprehensive study on the role of the activation forms, occurrence, and development of innate immunity and acquired immunity in the infection of animal-borne infectious disease pathogens. In addition, novel vaccines for the specific pathogens were attempted to develop. The purpose of exploration is to better understand the pathogenic mechanisms of animal-borne infectious diseases and develop effective biological products. The goal of this research topic is to provide a forum to advance research on the infection mechanisms of animal-borne infectious disease pathogens and the development of novel vaccines against these animal-borne diseases. Subtopics focusing on animal viruses include, but are not limited to: 1) Pathogenesis of animal-borne infectious disease pathogens such as avian influenza, Newcastle disease, African swine fever, Foot-and-mouth disease, Porcine epidemic diarrhea, peste des petits ruminants, infectious bronchitis, avian infectious bursal disease, infectious laryngotracheitis, Marek's disease, avian leukemia, etc. 2) Cellular and humoral immune responses to the pathogens of animal-borne infectious diseases. 3) The role of the pattern recognition receptor (PRR) of the dendritic cells in the recognition of pathogens. 4) Activation of immune cells and cell signal transduction induced by pathogens. 5) Immunosuppressive diseases and immune evasion. 6) Novel approaches to vaccine development include structure-based immunogen design, gene-based vaccine platforms, and the formulation of recombinant antigens with potent adjuvants.